The Umeå-based biotech company Omnio AB has raised 4.3 million euros from shareholders to advance its wound-healing drug, a recombinant form of plasminogen, to clinical trials. The funding will complete GMP manufacturing and facilitate preclinical studies, with Phase IIa trials expected to start in mid-2026. The new CEO, Felipe Velasquez, aims to expand the workforce and R&D capabilities.
Umeå biotech firm Vakona has secured funding from existing and new investors to advance its innovative acne treatment targeting skin microbiome imbalances. This financing will help complete product development and prepare for clinical trials, aided by academic collaboration.
Roger Folkhage has been appointed CEO of Umeå-based Medicvent, succeeding Erik Lindström. He aims to drive international expansion in workplace safety and healthcare, leveraging his sales experience. Folkhage recognizes the company's potential for growth and innovation in air pollutant evacuation solutions.
Umeå Biotech Incubator (UBI) has received 2.5 million SEK from Kempestiftelserna for 2026 to support research verification activities. This funding aids commercialization for researchers, solidifying UBI's position as a leading biotech incubator in Europe.
Nil Medical's "Vestpack" is undergoing clinical trials in Sweden and Finland, aiming to improve treatment experiences for pediatric cancer patients. The company seeks a Business & Sales Manager to support expansion and is exploring further opportunities internationally.
QureTech Bio AB has received a European patent for GmPcides, a new class of synthetic antibacterials effective against drug-resistant bacteria like MRSA. This patent guarantees protection until 2041.
Mucocort AB has been granted a patent in Australia for its medical technology innovation. The company has successfully developed M045A, an innovative mucoadhesive "patch" for the treatment of oral aphthous ulcers.
